臨床婦人科産科65巻10号

2011年10月発行

今月の臨床 子宮頸癌─予防と妊孕性温存のための治療戦略 予防戦略

3．HPVワクチンの臨床試験成績update

著者： 吉川裕之¹

所属機関： ¹筑波大学大学院人間総合科学研究科婦人周産期医学

ページ範囲：P.1216 - P.1219

　臨床試験でHPVワクチンの予防効果が確認されたのは，HPV16／18の持続感染と前癌病変であるCIN2／3，AIS発生についてであり，未感染者には100％近い効果がある^{1, 2）}．臨床治験ではおよそ15～25歳を対象としているが，一般対象にワクチンを接種する場合に100％近い効果があると誤解してはならない．あくまでHPV16やHPV18に未感染の場合である．治験の対象は数万人に達するが，関連のある重篤な有害事象は皆無に近い．2価ワクチン（HPV16／18，サーバリクス^®）と4価ワクチン（HPV6／11／16／18，ガーダシル^®）がある．HPVワクチンの最新（2009年以降）臨床試験データや勧告について紹介する．

参考文献

1） The FUTURE II Study Group : Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 356 : 1915─1927, 2007

2） Paavonen J, Naud P, Salmeron J, et al : Efficacy of human papillomavirus （HPV）-16／18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types （PATRICIA） : final analysis of a double-blind, randomised study in young women. Lancet 374 : 301─314, 2009

3） Centers for Disease Control and Prevention （CDC） : FDA licensure of bivalent human papillomavirus vaccine （HPV2, Cervarix） for use in females and updated HPV vaccination recommendations from the advisory committee on Immunization Practices （ACIP）. MMWR 59 : 626─629, 2010

4） Centers for Disease Control and Prevention （CDC） : FDA licensure of quadrivalent human papillomavirus vaccine （HPV4, Gardasil） for use in males and guidance from the advisory committee on immunization practices（ACIP）. MMWR 59 : 630─632, 2010

5） Einstein MH, Baron M, Levin MJ, et al : Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus （HPV） cervical cancer vaccines in healthy women aged 18─45 years. Hum Vaccines 5 : 702─716, 2009

6） Descamps D, Hardt K, Spiessens B, et al : Safety of human papillomavirus（HPV）-16／18 AS04-adjuvanted vaccine for cervical cancer prevention : a pooled analysis of 11 clinical trials. Human Vaccines 5 : 332─340, 2009

7） The GlaxoSmithKline Vaccine HPV-007 Study Group : Sustained efficacy and immunogenicity of the human papillomavirus（HPV）-16／18 AS04-adjuvanted vaccine : analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 : 1975─1985, 2009

8） David M-P, Van Herck K, Hardt K, et al : Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine : modeling of sustained antibody responses. Gynecol Oncol 115（3 Suppl 1） : S1─6, 2009

9） Konno R, Dobbelaere K, Godeaux O, et al : Immunogenicity, reactogenicity and safety of human papillomavirus 16／18 AS04-adjuvanted vaccine in Japanese women : interim analysis of a phase II double-blind, randomized controlled trial at Month 7. Int J Gynecol Cancer 19 : 905─911, 2009

10） Konno R, Tamura S, Dobbelaere K, et al : Efficacy of human papillomavirus 16／18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years : interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer 20 : 404─410, 2010

11） Konno R, Tamura S, Dobbelaere K, et al : Efficacy of human papillomavirus type 16／18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years : final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 20 : 847─855, 2010

12） 神谷　斎，奥谷まり絵 : 10～15歳の日本人健康女性を対象とした子宮頸癌予防ワクチンCervarixTM（HPV-16／18AS04アジュバントワクチン）の免疫原性と安全性の評価．小児臨床42 : 2451─2460, 2009

13） Konno R, Sasagawa T, Fukuda T, et al : Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer 20 : 385─392, 2010

14） Rowhani-Rahbar A, Mao C, Hughes JP, et al : Longer term efficacy of a prophylactic monovalent human papillomavirustype 16 vaccine. Vaccine 27 : 5612─5619, 2009

15） Brown DR, Kjaer SK, Sigurdsson K, et al : The Impact of quadrivalent human papillomavirus（HPV ; types 6, 11, 16, and 18） L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV─naive women aged 16─26 years. J Infect Dis 199 : 926─935, 2009

16） The FUTURE I／II Study Group : Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts : randomised controlled trial. BMJ 340 : c3493, 2010

17） Munoz N, Manalastas R Jr, Pitisuttithum P, et al : Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus （types 6, 11, 16, 18） recombinant vaccine in women aged 24─45 years : a randomised, double-blind trial. Lancet 373 : 1949─1957, 2009

18） Garland SM, Ault KA, Gall SA, et al : Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6／11／16／18 vaccine. a combined analysis of five randomized controlled trials. Obstet Gynecol 114 : 1179─1188, 2009

19） Fairley CK, Hocking JS, Gurrin LC, et al : Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85 : 499─502, 2009

20） Donovan B, Franklin N, Guy R, et al : Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia : analysis of national sentinel surveillance data. Lancet Infect Dis 11 : 39─44, 2010

21） Giuliano AR, Palefsky JM, Goldstone S et al : Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364 : 401─411, 2011